AIM ImmunoTech Inc. (AIM)
AIM trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.1699
-4.23% on the day
Market cap
$6.8M
Nano cap
Revenue · 2025
$88K
-48.2% on 2024
Net income · 2025
-$14.0M
-15861.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | AIM on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Not reported by the screener |
| IPO year | Not reported by the screener |
| SEC CIK | 0000946644 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $88K |
| Net income | -$14.0M |
| Operating income | -$11.7M |
| Net margin | -15861.4% |
| Operating margin | -13254.5% |
| Revenue growth | -48.2% |
| Cash | $3.0M |
| Total assets | $5.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 77.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-06-24 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-09-14 |
| Latest proxy | DEF 14A | 2026-09-30 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CELZ | Creative Medical Technology Holdings Inc. | $0.8199 | -2.51% | $6.2M |
| BTTC | Black Titan Corporation | $0.4380 | -10.70% | $6.0M |
| SNTI | Senti Biosciences Holdings Inc. | $0.2550 | -19.96% | $7.9M |
| LIMN | Liminatus Pharma Inc. | $3.41 | -1.16% | $4.6M |
| INTS | Intensity Therapeutics Inc. | $3.55 | +7.25% | $11.6M |
| INAB | IN8bio Inc. | $1.18 | -4.07% | $11.6M |
| PASG | Passage Bio Inc. | $3.64 | -20.00% | $11.7M |
| PLUR | Pluri Inc. | $0.9400 | -3.08% | $11.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier